Join our daily newsletter At The Bell to receive exclusive market insights
The ASX200 has been trading quite flat.
The IT sector has surged, up more than 2 per cent, while telecommunications is struggling, shedding about a per cent.
The Australian Bureau of Statistics (ABS) reported a 3.4 per cent rise in inflation for the year to January 2024, continuing the trend of the lowest annual rate since November 2021.
Now, in this mid-session update, we’ll discuss Neuren Pharmaceuticals, Orcoda, Augustus Minerals, and Little Green Pharma.
One of the top-trending stories on HotCopper is Neuren Pharmaceuticals (ASX:NEU). The company posted strong Q4 2023 sales of its flagship drug DAYBUE to US$87.1 million.
Despite this, Neuren shares have slumped 12 per cent.
This could be linked to a recent incident where Neuren shares plunged following a report from US short-selling firm Culper Research, accusing Neuren partner Acadia of dishonest reporting.
NEU had been trading at $18.77.
Integrated technology company Orcoda (ASX:ODA) has welcomed Maree Adshead as an independent Non-Executive Director.
She holds more than 30 years of board and advisory experience in Australia, and she currently serves as Chair at Turbine Sunshine Coast and was the CEO of Eco-Markets Australia.
ODA had been trading at 25.5 cents.
Augustus Minerals (ASX:AUG) geotechnical teams are set to begin fieldwork at its Ti-Tree Shear project in Western Australia, in which 4000 soil samples have been gathered.
The company’s exploration focus is on gold, lithium, and copper, and underexplored sections within the Ti-Tree zone. Completion is expected by Q2 FY24.
AUG had been trading at 4.1 cents.
Little Green Pharma (ASX:LGP) has shipped its first batch of its Desert Flame cannabis flower products to Poland.
This follows a three-year process, with Polish Marketing Authorisation from a health regulator, and will be distributed by LGP’s partner, Medezin.
LGP is the first Australian company to enter the Polish cannabis market.
LGP had been trading at 14.5 cents.
